招商证券股份有限公司 关于迈克生物股份有限公司 2024 年度募集资金存放及使用的核查意见 招商证券股份有限公司（以下简称"招商证券"）作为迈克生物股份有限公司 （以下简称"迈克生物"、"公司"）向特定对象发行股票的保荐机构，根据《证券 发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易所 上市公司自律监管指引第 13 号—保荐业务》等有关规定，对公司 2024 年度募集 资金存放及使用情况进行了核查，具体情况如下： 一、 募集资金基本情况 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发 行股票注册的批复》（证监许可〔2021〕412 号）的核准，公司本次向特定对象发 行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资金 总额为人民币 1,574,160,000.00 元，扣除发行费用人民币（不含增值税） 16,703,564.36 元，实际募集资金净额为人民币 1,557,45 ...

内部控制审计报告 二〇二四年度 内部控制审计报告 信会师报字[2025]第 ZD10072 号 迈克生物股份有限公司 迈克生物股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了迈克生物股份有限公司（以下简称迈克生物）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是迈克生物董事会的责任。 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 四、 财务报告内部控制审计意见 内控审计报告 第 1 页 我们认为，迈克生物于 2024 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 立信会计师事务所 中国注册会计师： （特殊普通合伙） 二、 注册会计师的责任 我们的责任是在实施审计工作 ...

独立董事 2024 年度述职报告 各位股东及股东代表： 作为迈克生物股份有限公司（以下简称"公司"）第四届、第五届董事会独立董事，2024 年度，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司独立董事管理办法》（以下简称"《管理办 法》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以 下简称"《创业板上市公司规范运作》"）等相关法律法规的规范要求，以及《公司章程》《独 立董事工作制度》的相关制度赋予的权利和义务，诚信、勤勉、尽责、忠实地履行职责，及时 了解公司的生产经营及发展情况，积极出席相关会议，对各项议案进行认真审议，发挥专业特 长，为公司经营发展提出合理化建议，有效维护了公司整体利益和全体股东的合法权益。现就 本人 2024 年度履行独立董事职责情况汇报如下： 一、本人基本情况、任职资格及独立性说明 本人，傅代国，1964 年 10 月出生，中国国籍，无境外永久居留权，博士学历。曾任川润 股份有限公司独立董事、利尔化学股份有限公司独立董事、北方君正集成电路股份有限公司独 立董事、四川郎酒 ...

独立董事 2024 年度述职报告 各位股东及股东代表： 作为迈克生物股份有限公司（以下简称"公司"）第五届董事会独立董事，2024 年度，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司独立董事管理办法》（以下简称"《管理办法》"）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称 "《创业板上市公司规范运作》"）等相关法律法规的规范要求，以及《公司章程》《独立董 事工作制度》的相关制度赋予的权利和义务，诚信、勤勉、尽责、忠实地履行职责，及时了解 公司的生产经营及发展情况，积极出席相关会议，对各项议案进行认真审议，发挥专业特长， 为公司经营发展提出合理化建议，有效维护了公司整体利益和全体股东的合法权益。现就本人 2024 年度履行独立董事职责情况汇报如下： 一、本人基本情况、任职资格及独立性说明 本人，梁开成先生，1956 年出生，中国国籍，无境外永久居留权，大专学历。始终专注 于医学检验专业，长期从事医学检验产品的研发、经营与应用，拥有数十年的医学检验行业从 业经验，对医学检验专业有深刻的 ...

Financial Performance - The company reported a significant decline in performance, with detailed reasons provided in the "Management Discussion and Analysis" section of the annual report[3]. - Maccura Biotechnology reported a revenue of 1.2 billion CNY for the fiscal year 2023, representing a 15% increase compared to the previous year[23]. - The company achieved a net profit of 300 million CNY, which is a 20% growth year-over-year[23]. - The company's operating revenue for 2024 was ¥2,548,756,678.60, a decrease of 11.98% compared to ¥2,895,769,512.02 in 2023[28]. - The net profit attributable to shareholders for 2024 was ¥126,805,274.84, down 59.44% from ¥312,618,556.85 in 2023[28]. - The cash flow from operating activities for 2024 was ¥633,798,557.62, representing a decline of 29.70% from ¥901,510,121.99 in 2023[28]. - The basic earnings per share for 2024 was ¥0.2091, a decrease of 59.29% compared to ¥0.5136 in 2023[28]. - The company reported a net profit of -¥154,567,061.57 in Q4 2024, indicating a significant loss compared to previous quarters[30]. - The company achieved total revenue of 2.55 billion, a year-on-year decrease of 11.98%[82]. - Net profit attributable to shareholders was 127 million, down 59.44% year-on-year, primarily due to goodwill impairment loss of 94 million[79]. Dividend Distribution - The company plans to distribute a cash dividend of 1.04 RMB per 10 shares, based on a total of 608,511,590 shares[12]. - The company plans to distribute a cash dividend of 1.55 RMB per 10 shares, totaling 94,058,297.22 RMB (including tax) based on a share base of 606,827,724 shares[193]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by 2025[23]. - Maccura aims to achieve a revenue target of 1.5 billion CNY for 2024, reflecting a 25% growth forecast[23]. - The company is focusing on enhancing laboratory solutions through a full lifecycle service model, aiming for efficient construction and intelligent operation of laboratories[78]. - The company is actively pursuing market expansion through the introduction of new products and technologies[96]. - The company is committed to enhancing its product offerings in the healthcare sector, particularly in diagnostics[96]. Research and Development - The company is investing in R&D to enhance its core technologies and reduce reliance on imported raw materials, aiming to increase self-sufficiency in key materials[11]. - Maccura has allocated 200 million CNY for R&D in 2024, emphasizing advancements in digital PCR technology[23]. - The company has invested over 16.7 billion yuan in R&D over the past five years, with R&D expenses accounting for 21.91% of self-developed product revenue in the latest reporting period[66]. - The company has completed 75 new R&D projects and filed 582 domestic patents, showcasing its commitment to innovation[67]. - The company has a systematic R&D capability, covering major technical fields such as biochemistry, immunology, and molecular diagnostics[53]. Product Development and Innovation - Maccura plans to launch three new products in the next quarter, focusing on molecular diagnostics and rapid testing technologies[23]. - The company has developed a comprehensive product line covering over 80% of laboratory testing projects, including biochemical, immunological, and molecular diagnostics[50]. - The company has registered 518 in vitro diagnostic products, covering 80% of project needs for various medical institutions[63]. - The company has achieved a self-supply rate of core raw materials of 60% in the last five years, contributing to cost optimization[60]. - The company has registered multiple new products in Colombia, including blood cell analysis reagents and immunoassay kits, further diversifying its market presence[102]. Regulatory Compliance and Risk Management - The company is closely monitoring regulatory changes and adjusting its business strategies accordingly to align with new market rules[4]. - The company acknowledges the risks associated with technological innovation and is enhancing its confidentiality measures to protect core technologies[8]. - The company is facing risks from policy changes in the in vitro diagnostics industry, which may impact operational strategies if not adapted timely[5]. - The implementation of centralized procurement policies is expected to exert downward pressure on product prices across the IVD industry, impacting sales for all companies involved[48]. Governance and Management - The company has a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with corporate governance standards[151]. - The board of directors held 10 meetings during the reporting period, reviewing 37 proposals, which laid a solid foundation for achieving annual goals[153]. - The company has a total of 9 senior management personnel as of the end of the reporting period[170]. - The company has implemented a stock incentive plan for its executives, with specific shares allocated for performance incentives[161]. - The company has a diverse management team with extensive experience in the medical diagnostics industry, ensuring effective leadership[164]. Financial Management - The total cash inflow from operating activities was CNY 3,079,455,479.50, while the total cash outflow was CNY 2,445,656,921.88[115]. - The company has a total of 107,954.3 hours of outsourced labor, with total payments amounting to 3,014,597.50 RMB[192]. - The company has a salary management system that includes basic salary, performance bonuses, year-end bonuses, and other benefits[177]. - The company has not issued any new shares or stock bonuses in the current profit distribution plan, focusing solely on cash dividends[196]. - The company has a total of 0 shares held by independent director Fu Daiguo, with no changes during the period[161].

Financial Performance - The company's revenue for Q1 2025 was ¥510,257,588.90, a decrease of 17.22% compared to ¥616,367,154.02 in the same period last year[5] - Net profit attributable to shareholders was ¥23,979,615.55, down 80.09% from ¥120,442,248.90 year-on-year[5] - Total revenue for the current period was CNY 510,257,588.90, a decrease of 17.2% from CNY 616,367,154.02 in the previous period[25] - Net profit for the current period was CNY 25,453,793.22, down 79.5% from CNY 124,243,826.11 in the previous period[26] - The total comprehensive income attributable to the parent company was 9,189,511.39 yuan, compared to 120,078,599.54 yuan in the previous period, indicating a significant decrease[27] - Basic and diluted earnings per share were both 0.0392 yuan, a decrease from 0.1967 yuan in the previous period[27] Cash Flow - The net cash flow from operating activities increased significantly to ¥55,566,947.10, up 1,037.67% from ¥4,884,287.66 in the previous year[5] - The net cash flow from operating activities was 55,566,947.10 yuan, a substantial increase from 4,884,287.66 yuan in the previous period[30] - The company reported a net cash flow from investing activities of -98,479,050.23 yuan, worsening from -39,461,178.86 yuan year-over-year[30] - The net cash flow from financing activities was 164,186,410.20 yuan, a significant increase from 16,166,025.50 yuan in the previous period[30] - The company received cash from operating activities totaling 674,117,346.67 yuan, down from 765,844,742.92 yuan in the previous period[30] - The company incurred cash outflows from operating activities amounting to 618,550,399.57 yuan, compared to 760,960,455.26 yuan in the previous period[30] - The company received 266,591,057.03 yuan in cash from financing activities, up from 134,152,157.14 yuan in the previous period[30] Assets and Liabilities - The company's total assets as of March 31, 2025, were ¥8,062,296,715.22, reflecting a slight increase of 1.08% from ¥7,976,306,737.10 at the end of the previous year[5] - Current assets totaled CNY 3,683,847,388.76, slightly up from CNY 3,639,623,036.94, indicating a 1.2% increase[23] - The company's cash and cash equivalents rose to CNY 772,110,836.36 from CNY 671,453,066.24, an increase of 15.0%[22] - Short-term borrowings increased significantly to CNY 377,574,410.46 from CNY 255,095,896.66, a rise of 48.0%[24] - Total liabilities rose to CNY 1,634,262,242.93 from CNY 1,552,644,190.08, marking an increase of 5.2%[24] - The company reported a decrease in accounts receivable to CNY 1,441,264,557.07 from CNY 1,563,178,437.53, a decline of 7.8%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,022[13] - The largest shareholder, Tang Yong, holds 11.11% of shares, totaling 68,062,301 shares, with 17,700,000 shares pledged[13] - The second-largest shareholder, Wang Dengming, owns 7.43% of shares, amounting to 45,534,495 shares[13] - The total number of shares held by the top 10 unrestricted shareholders includes 35,774,906 shares held by Guo Lei[14] - The company has a total of 2,897,200 restricted shares at the end of the reporting period, with 686,375 shares added during the period[16] Strategic Changes - The company's strategic shift from direct sales to agency products led to a 49.28% decline in agency product sales, while self-owned products saw a 3.23% decrease[10] - The company plans to focus on core business and optimize resource allocation following the sale of Shanxi Mike[20] - The company has a total of 52% equity in Shanxi Mike, which was sold for 8.284 million RMB to Taiyuan Ruiguang Hospital Management Co., Ltd[20] Management and Governance - Management expenses rose by 33.89% to ¥43,771,432.52, primarily due to increased severance payments and intangible asset amortization[10] - The sixth board of directors consists of 9 members, including 6 non-independent directors and 3 independent directors[19] - The company will hold its first temporary shareholders' meeting on January 13, 2025, to elect the sixth board of directors and supervisory board[18] - The company has appointed Wu Mingjian as the general manager and Shi Wei as the board secretary and strategic investment director[19] Investment and Research - The company’s investment income decreased by 63.57% to ¥673,958.18, attributed to lower returns from financial products[10] - Research and development expenses were CNY 61,571,017.19, slightly up from CNY 59,524,079.57, reflecting a 3.4% increase[26] Asset Disposal - The company experienced a 147.16% increase in asset disposal losses, amounting to ¥3,422,590.39, compared to ¥1,384,763.40 in the previous year[11]

募集资金到位情况业经立信会计师事务所（特殊普通合伙）于2022年1月26日出具信会师 报字[2022]第ZD10018号《验资报告》审验。公司对募集资金采取专户存储制度。 证券代码:300463 证券简称:迈克生物 公告编号:2025-020 迈克生物股份有限公司 关于部分募集资金专用账户注销完成的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册的 批复》（证监许可〔2021〕412号）的核准，迈克生物股份有限公司（以下简称"公司"）本次向 特定对象发行人民币普通股（A股）56,000,000股，每股发行价格为28.11元/股，募集资金总额 为人民币1,574,160,000.00元，扣除发行费用人民币（不含增值税）16,703,564.36元，实际募集 资金净额为人民币1,557,456,435.64元。 三、本次的募集资金专户注销情况 二、募集资金存放与管理 为规范募集资金的管理，保护投资者利益，公司按照《深圳证券交易所创业板股票上市规 则》《上市公司自律 ...

最新一期业绩显示，2024年三季报，公司实现营业收入19.48亿元，同比-7.92%；净利润2.81亿元，同比 4.72%，销售毛利率57.19%。 迈克生物股份有限公司主要从事体外诊断产品研发、生产、销售和服务。公司主营产品包括自产和代理 诊断试剂及诊断仪器。公司产品具备国际一流的品质,是国内IVD企业最早建立量值溯源系统的公司， 也是国际医学量值溯源体系国际检验医学溯源联合委员会（JCTLM)中首家中国企业代表。 序号股票简称PE(TTM)PE(静)市净率总市值(元)52迈克生物22.2923.201.1172.52亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261. ...

迈克生物股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 证券代码：300463 证券简称：迈克生物 公告编号：2025-019 迈克生物股份有限公司第六届董事会第二次会议、第六届监事会第二次会议审议通过了 《关于继续使用部分闲置募集资金进行现金管理的议案》，为提高暂时闲置募集资金的使用效 率，增加资金收益，在保证募集资金投资项目建设和募集资金正常使用的情况下，同意使用不 超过人民币6,000万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、满足 保本要求的理财产品，自公司第六届董事会第二次会议审议通过之日起十二个月内有效，在上 述使用期限及额度内，资金可以循环滚动使用。闲置募集资金现金管理到期后将及时归还至募 集资金专户，同时授权公司董事长行使相关投资决策权，财务负责人办理具体相关事宜。公司 已于2025年3月7日在巨潮资讯网刊登了《关于继续使用部分闲置募集资金进行现金管理的公告》 （公告编号：2025-012）。 近日，公司使用部分闲置募集资金购买的理财产品已到期赎回，并继续使用人民币 ...